Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated bid cleavage

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 1, 2010, Pages 316-325

  Tomicic, Maja T ^a   Christmann, Markus ^a   Kaina, Bernd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSOME; CASPASE 2; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 9; CYTOCHROME C; HISTONE H2AX; PIFITHRIN ALPHA; PROTEASOME; PROTEIN BCL XL; PROTEIN BID; PROTEIN P53; SMALL INTERFERING RNA; SURVIVIN; TOPOTECAN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; FIBROBLAST; GLIOMA CELL; HUMAN; HUMAN CELL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; WILD TYPE;

ANIMALS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, WESTERN; CASPASE 2; CASPASE 3; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DOWN-REGULATION; FIBROBLASTS; FLOW CYTOMETRY; HISTONES; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHORYLATION; RNA, SMALL INTERFERING; TOPOTECAN; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 73949110695     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.159962     Document Type: Article

References (40)

1. Blumenthal RD, Leone E, Goldenberg DM, Rodriguez M, and Modrak D (2004) An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. Int J Cancer 108:293-300.
2. Christmann M, Tomicic MT, Origer J, and Kaina B (2005) Fen1 is induced p53 dependently and involved in the recovery from UV-light-induced replication inhibition. Oncogene 24:8304-8313.
3. Christmann M, Tomicic MT, Roos WP, and Kaina B (2003) Mechanisms of human DNA repair: an update. Toxicology 193:3-34.
4. Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, and Marks JR (1998) Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res 18:2919-2932.
5. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, and Reed JC (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17:2215-2223.
6. Deveraux QL, Takahashi R, Salvesen GS, and Reed JC (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-304.
7. Esposti MD (2002) The roles of Bid. Apoptosis 7:433-440.
8. Franklin EE and Robertson JD (2007) Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis. Biochem J 405:115-122.
9. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, et al. (2003) Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278:20303-20312.
10. Goldwasser F, Bae I, Valenti M, Torres K, and Pommier Y (1995) Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55:2116-2121.
11. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56:4430-4437.
12. Gu L, Zhu N, Zhang H, Durden DL, Feng Y, and Zhou M (2009) Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 15:363-375.
13. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, and Alnemri ES (2002) Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 277:13430-13437.
14. Hertzberg RP, Caranfa MJ, and Hecht SM (1989) On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638.
15. Hsiang YH, Lihou MG, and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
16. Krumschnabel G, Sohm B, Bock F, Manzl C, and Villunger A (2009) The enigma of caspase-2: the laymen's view. Cell Death Differ 16:195-207.
17. Lackinger D and Kaina B (2000) Primary mouse fibroblasts deficient for c-Fos, p53 or for both proteins are hypersensitive to UV light and alkylating agent-induced chromosomal breakage and apoptosis. Mutat Res 457:113-123.
18. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, and Altieri DC (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1:461-466.
19. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, and Altieri DC (1998a) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580-584.
20. Li H, Zhu H, Xu CJ, and Yuan J (1998b) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501.
21. Lin Y, Ma W, and Benchimol S (2000) Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet 26:122-127.
22. Manzl C, Krumschnabel G, Bock F, Sohm B, Labi V, Baumgartner F, Logette E, Tschopp J, and Villunger A (2009) Caspase-2 activation in the absence of PIDDosome formation. J Cell Biol 185:291-303.
23. Milosevic J, Hoffarth S, Huber C, and Schuler M (2003) The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases. Oncogene 22:6852-6856.
24. Miyashita T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
25. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, et al. (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188:2033-2045.
26. Nitiss JL and Wang JC (1996) Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 50:1095-1102.
27. Norbury CJ and Zhivotovsky B (2004) DNA damage-induced apoptosis. Oncogene 23:2797-2808.
28. Porter SE and Champoux JJ (1989) The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 17:8521-8532.
29. Schmidt F, Rieger J, Wischhusen J, Naumann U, and Weller M (2001) Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Eur J Pharmacol 412:21-25.
30. 2/M checkpoint maintenance. Cell 136:508-520.
31. Slee EA, Keogh SA, and Martin SJ (2000) Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ 7:556-565.
32. Tinel A and Tschopp J (2004) The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 304:843-846.
33. Tomicic MT, Bey E, Wutzler P, Thust R, and Kaina B (2002a) Comparative analysis of DNA breakage, chromosomal aberrations and apoptosis induced by the antiherpes purine nucleoside analogues aciclovir, ganciclovir and penciclovir. Mutat Res 505:1-11.
34. Tomicic MT, Christmann M, and Kaina B (2005a) Apoptosis in UV-C light irradiated p53 wild-type, apaf-1 and p53 knockout mouse embryonic fibroblasts: interplay of receptor and mitochondrial pathway. Apoptosis 10:1295-1304.
35. Tomicic MT, Christmann M, and Kaina B (2005b) Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res 65: 8920-8926.
36. Tomicic MT, Thust R, and Kaina B (2002b) Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene 21:2141-2153.
37. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, and Choo KH (2000) Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 10:1319-1328.
38. Wagner S, Peters O, Fels C, Janssen G, Liebeskind AK, Sauerbrey A, Suttorp M, Hau P, and Wolff JE (2008) Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. J Neurooncol 86:175-181.
39. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, and WellerM(2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22:8233-8245.
40. Ziporen L, Donin N, Shmushkovich T, Gross A, and Fishelson Z (2009) Programmed necrotic cell death induced by complement involves a Bid-dependent pathway. J Immunol 182:515-521.